NFATs and Alzheimer's disease

Molecular and Cellular Pharmacology

Volumn 2, Issue 1, 2010, Pages 7-14

  Abdul, Hafiz Mohmmad ^a   Furman, Jennifer L ^b   Sama, Michelle A ^b,c   Mathis, Diana M ^b   Norris, Christopher M ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Alzheimer's disease; Calcineurin; Neurodegenerative disorders; NFATs

Indexed keywords

AMYLOID BETA PROTEIN; CALCINEURIN; CALCINEURIN INHIBITOR; GLUTAMIC ACID; IMMUNOSUPPRESSIVE AGENT; ISOLEUCYLVALYLGLUTAMYLGLUTAMYLTHREONINE; PEPTIDE DERIVATIVE; TACROLIMUS; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG; VALYLISOLEUCYLVALYLISOLEUCYLTHREONINE;

ALZHEIMER DISEASE; AUTOPSY; COGNITION; DEGENERATIVE DISEASE; DEMENTIA; DISEASE COURSE; GLIA CELL; HIPPOCAMPUS; HUMAN; NERVE CELL NECROSIS; NERVOUS TISSUE; NONHUMAN; NOTE; POSITIVE FEEDBACK; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

EID: 77953436592     PISSN: None     EISSN: 19381247     Source Type: Journal    
DOI: 10.4255/mcpharmacol.10.02     Document Type: Note

References (49)

1. Gibson GE, Peterson C. Calcium and the aging nervous system. Neurobiol Aging 1987;8:329-43.
2. Khachaturian ZS. Towards theories of brain aging. In: Kay DW, Burrows GW, editors. Handbook of Studies on Psychiatry and Old Age. Amsterdam: Elsevier; 1984. p. 7-30.
3. 2+-dependent afterhyperpolarizations in hippocampal neurons of aged rats. Science 1984;226:1089-92.
4. Thibault O, Gant JC, Landfield PW. Expansion of the calcium hypothesis of brain aging and Alzheimer's disease: minding the store. Aging Cell 2007;6:307-17.
5. Green KN, LaFerla FM. Linking calcium to Abeta and Alzheimer's disease. Neuron 2008;59:190-94.
6. Mattson MP. Calcium and neurodegeneration. Aging Cell 2007;6:337-50.
7. Abdul HM, Sama MA, Furman JL, et al. Cognitive decline in Alzheimer's disease is associated with selective changes in calcineurin/NFAT signaling. J Neurosci 2009;29:12957-69.
8. Aramburu J, Rao A, Klee CB. Calcineurin: from structure to function. Curr Top Cell Regul 2000;36:237-95.
9. Polli JW, Billingsley ML, Kincaid RL. Expression of the calmodulin-dependent protein phosphatase, calcineurin, in rat brain: developmental patterns and the role of nigrostriatal innervation. Brain Res Dev Brain Res 1991;63:105-19.
10. Winder DG, Mansuy IM, Osman M, Moallem TM, Kandel ER. Genetic and pharmacological evidence for a novel, intermediate phase of long-term potentiation suppressed by calcineurin. Cell 1998;92:25-37.
11. Halpain S, Hipolito A, Saffer L. Regulation of F-actin stability in dendritic spines by glutamate receptors and calcineurin. J Neurosci 1998;18:9835-44.
12. 2+-induced apoptosis through calcineurin dephosphorylation of BAD. Science 1999;284:339-43.
13. Norris CM, Kadish I, Blalock EM, et al. Calcineurin triggers reactive/inflammatory processes in astrocytes and is upregulated in aging and Alzheimer's models. J Neurosci 2005;25:4649-58.
14. Cho HJ, Jin SM, Youn HD, Huh K, Mook-Jung I. Disrupted intracellular calcium regulates BACE1 gene expression via nuclear factor of activated T cells 1 (NFAT 1) signaling. Aging Cell 2008;7:137-47.
15. Mansuy IM, Mayford M, Jacob B, Kandel ER, Bach ME. Restricted and regulated overexpression reveals calcineurin as a key component in the transition from short-term to long-term memory. Cell 1998;92:39-49.
16. 2+ dysregulation with brain aging. J Neurosci 2001;21:4066-73.
17. Reese LC, Zhang W, Dineley KT, Kayed R, Taglialatela G. Selective induction of calcineurin activity and signaling by oligomeric amyloid beta. Aging Cell 2008;7:824-35.
18. Agostinho P, Lopes JP, Velez Z, Oliveira CR. Overactivation of calcineurin induced by amyloid-beta and prion proteins. Neurochem Int 2008;52:1226-33.
19. Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D. Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 2009;62:788-801.
20. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 2007;27:2866-75.
21. Snyder EM, Nong Y, Almeida CG, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 2005;8:1051-58.
22. Kuchibhotla KV, Goldman ST, Lattarulo CR, Wu HY, Hyman BT, Bacskai BJ. Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron 2008;59:214-25.
23. Dineley KT, Hogan D, Zhang WR, Taglialatela G. Acute inhibition of calcineurin restores associative learning and memory in Tg2576 APP transgenic mice. Neurobiol Learn Mem 2007;88:217-24.
24. Liu F, Grundke-Iqbal I, Iqbal K, Oda Y, Tomizawa K, Gong CX. Truncation and activation of calcineurin A by calpain I in Alzheimer disease brain. J Biol Chem 2005;280:37755-62.
25. 2+/calcineurin-NFAT-mediated signaling. Mol Cells 2004;18:1-9.
26. Fernandez AM, Fernandez S, Carrero P, Garcia-Garcia M, Torres-Aleman I. Calcineurin in reactive astrocytes plays a key role in the interplay between proinflammatory and anti-inflammatory signals. J Neurosci 2007;27:8745-56.
27. Graef IA, Mermelstein PG, Stankunas K, et al. L-type calcium channels and GSK-3 regulate the activity of NF-ATc4 in hippocampal neurons. Nature 1999;401:703-708.
28. Luoma JI, Zirpel L. Deafferentation-induced activation of NFAT (nuclear factor of activated T-cells) in cochlear nucleus neurons during a developmental critical period: a role for NFATc4-dependent apoptosis in the CNS. J Neurosci 2008;28:3159-69.
29. Sama MA, Mathis DM, Furman JL, et al. Interleukin-1beta-dependent signaling between astrocytes and neurons depends critically on astrocytic calcineurin/NFAT activity. J Biol Chem 2008;283:21953-64.
30. Shioda N, Han F, Moriguchi S, Fukunaga K. Constitutively active calcineurin mediates delayed neuronal death through Fas-ligand expression via activation of NFAT and FKHR transcriptional activities in mouse brain ischemia. J Neurochem 2007;102:1506-17.
31. Vihma H, Pruunsild P, Timmusk T. Alternative splicing and expression of human and mouse NFAT genes. Genomics 2008;92:279-91.
32. Furman JL, Abdul HM, Xiong S, et al. Hippocampal cytokine expression and calcineurin/NFAT signaling associated with pre-clinical Alzheimer's disease and mild cognitive impairment. Soc Neurosci Abs 2009;39:727.24.
33. Su JH, Anderson AJ, Cribbs DH, et al. Fas and Fas ligand are associated with neuritic degeneration in the AD brain and participate in beta-amyloid-induced neuronal death. Neurobiol Dis 2003;12:182-93.
34. Wu H-Y, Hudry E, Hashimoto T, Grosskreutz C, Hyman B. Dysregulation of calcinerin/NFAT links abeta to neurodegeneration in Alzheimer's disease. Soc Neurosci Abs 2009;39:725.29.
35. Benedito AB, Lehtinen M, Massol R, et al. The transcription factor NFAT3 mediates neuronal survival. J Biol Chem 2005;280:2818-25.
36. Vashishta A, Habas A, Pruunsild P, Zheng JJ, Timmusk T, Hetman M. Nuclear Factor of Activated T-Cells Isoform c4 (NFATc4/NFAT3) as a Mediator of Antiapoptotic Transcription in NMDA Receptor-Stimulated Cortical Neurons. J Neurosci 2009;29:15331-40.
37. Groth RD, Mermelstein PG. Brain-derived neurotrophic factor activation of NFAT (nuclear factor of activated T-cells)-dependent transcription: a role for the transcription factor NFATc4 in neurotrophin-mediated gene expression. J Neurosci 2003;23:8125-34.
38. Fukumoto H, Cheung BS, Hyman BT, Irizarry MC. Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 2002;59:1381-89.
39. Cho HJ, Son SM, Jin SM, et al. RAGE regulates BACE1 and Abeta generation via NFAT1 activation in Alzheimer's disease animal model. FASEB J 2009;23:2639-49.
40. Taglialatela G, Hogan D, Zhang WR, Dineley KT. Intermediate- and long-term recognition memory deficits in Tg2576 mice are reversed with acute calcineurin inhibition. Behav Brain Res 2009; 8:95-9.
41. Yoshiyama Y, Higuchi M, Zhang B, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007;53:337-51.
42. Krensky A. Immunosuppressants, Tolerogens, and immunostimulants. In: Brunton L, Lazo J, Parker K, editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11 edition. New York: McGraw Hill; 2006. p. 1405-32.
43. Aliabadi AZ, Zuckermann AO, Grimm M. Immunosuppressive therapy in older cardiac transplant patients. Drugs Aging 2007;24:913-32.
44. Aramburu J, Yaffe MB, Lopez-Rodriguez C, Cantley LC, Hogan PG, Rao A. Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science 1999;285:2129-33.
45. Noguchi H, Matsushita M, Okitsu T, et al. A new cell-permeable peptide allows successful allogeneic islet transplantation in mice. Nat Med 2004;10:305-09.
46. Siman R, Reaume AG, Savage MJ, et al. Presenilin-1 P264L knock-in mutation: differential effects on abeta production, amyloid deposition, and neuronal vulnerability. J Neurosci 2000;20:8717-26.
47. Murphy MP, Beckett TL, Ding Q, et al. Abeta solubility and deposition during AD progression and in APPxPS-1 knock-in mice. Neurobiol Dis 2007;27:301-11.
48. DiCarlo G, Wilcock D, Henderson D, Gordon M, Morgan D. Intrahippocampal LPS injections reduce Abeta load in APP+PS1 transgenic mice. Neurobiol Aging 2001;22:1007-12.
49. Shaftel SS, Griffin WS, O'Banion MK. The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J Neuroinflammation 2008;5:7.